A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Lenalidomide (Primary) ; Bevacizumab; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 20 Aug 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.